159 related articles for article (PubMed ID: 11023974)
21. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
22. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC
Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055
[TBL] [Abstract][Full Text] [Related]
23. The p53 tumor suppressor gene and gene product.
Levine AJ
Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
[TBL] [Abstract][Full Text] [Related]
24. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif.
Ragimov N; Krauskopf A; Navot N; Rotter V; Oren M; Aloni Y
Oncogene; 1993 May; 8(5):1183-93. PubMed ID: 8479742
[TBL] [Abstract][Full Text] [Related]
25. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells.
Roger L; Jullien L; Gire V; Roux P
J Cell Sci; 2010 Apr; 123(Pt 8):1295-305. PubMed ID: 20332115
[TBL] [Abstract][Full Text] [Related]
26. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
27. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.
Kakudo Y; Shibata H; Otsuka K; Kato S; Ishioka C
Cancer Res; 2005 Mar; 65(6):2108-14. PubMed ID: 15781620
[TBL] [Abstract][Full Text] [Related]
28. In vitro analysis of the dominant negative effect of p53 mutants.
Chène P
J Mol Biol; 1998 Aug; 281(2):205-9. PubMed ID: 9698540
[TBL] [Abstract][Full Text] [Related]
29. The role of mutant p53 in human cancer.
Goh AM; Coffill CR; Lane DP
J Pathol; 2011 Jan; 223(2):116-26. PubMed ID: 21125670
[TBL] [Abstract][Full Text] [Related]
30. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription.
Miller CW; Chumakov A; Said J; Chen DL; Aslo A; Koeffler HP
Oncogene; 1993 Jul; 8(7):1815-24. PubMed ID: 8510927
[TBL] [Abstract][Full Text] [Related]
31. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the effect of mutant and wild-type p53 on global gene expression.
O'Farrell TJ; Ghosh P; Dobashi N; Sasaki CY; Longo DL
Cancer Res; 2004 Nov; 64(22):8199-207. PubMed ID: 15548685
[TBL] [Abstract][Full Text] [Related]
33. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
Mizuarai S; Yamanaka K; Kotani H
Cancer Res; 2006 Jun; 66(12):6319-26. PubMed ID: 16778209
[TBL] [Abstract][Full Text] [Related]
34. p53 transactivation domain mutant Q22, S23 is impaired for repression of promoters and mediation of apoptosis.
Roemer K; Mueller-Lantzsch N
Oncogene; 1996 May; 12(10):2069-79. PubMed ID: 8668332
[TBL] [Abstract][Full Text] [Related]
35. Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53.
Bristow RG; Peacock J; Jang A; Kim J; Hill RP; Benchimol S
Oncogene; 2003 May; 22(19):2960-6. PubMed ID: 12771947
[TBL] [Abstract][Full Text] [Related]
36. Prion-like aggregation of mutant p53 in cancer.
Silva JL; De Moura Gallo CV; Costa DC; Rangel LP
Trends Biochem Sci; 2014 Jun; 39(6):260-7. PubMed ID: 24775734
[TBL] [Abstract][Full Text] [Related]
37. Tumour associated mutants of p53 can inhibit transcriptional activity of p53 without heterooligomerization.
Jõers A; Kristjuhan A; Kadaja L; Maimets T
Oncogene; 1998 Nov; 17(18):2351-8. PubMed ID: 9811466
[TBL] [Abstract][Full Text] [Related]
38. Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer.
Hassan NM; Tada M; Hamada J; Kashiwazaki H; Kameyama T; Akhter R; Yamazaki Y; Yano M; Inoue N; Moriuchi T
Cancer Lett; 2008 Oct; 270(1):108-19. PubMed ID: 18555592
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of radiation-induced G2 delay potentiates cell death by apoptosis and/or the induction of giant cells in colorectal tumor cells with disrupted p53 function.
Bracey TS; Williams AC; Paraskeva C
Clin Cancer Res; 1997 Aug; 3(8):1371-81. PubMed ID: 9815821
[TBL] [Abstract][Full Text] [Related]
40. Mutant p53: "gain of function" through perturbation of nuclear structure and function?
Deppert W; Göhler T; Koga H; Kim E
J Cell Biochem Suppl; 2000; Suppl 35():115-22. PubMed ID: 11389540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]